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At present, both hematologists and obstetricians seem to 
avoid excess interventions in managing moderate immune 
thrombocytopenic purpura (ITP, defined as a platelet count of 
40,000– 60,000 ml 1) in pregnancy [1,2]. On the other hand, 
it is true that pregnant women with severe ITP (defined as a 
platelet count of less than 20,000 ml 1) often require 
aggressive intervention, e.g., treatment with a combination 
of drugs, splenectomy, and Cesarean section [2]. Accordingly, 
combination therapy of high-dose intravenous immunoglobulin 
(IVIG) and corticosteroids is the main course of 
management, even in severe patients. We report here on a 
pregnant woman with severe and refractory ITP (platelet 
count of about 1000 ml 1 or more less) who was managed 
with combination therapy of high-dose IVIG and corticosteroids 
together with short-term danazol in the third trimester. 
We also discuss the benefits of high-dose IVIG combined 
with corticosteroids, and risks of management with danazol. 
A 30-year-old nulligravid Japanese woman, who was 
diagnosed 5 years earlier with severe chronic ITP associated 
with a positive serologic test for antiphospholipid antibody, 
became pregnant under permission of the physician in 
charge. Before pregnancy, she was given 10 mg/day 
prednisone and 200 mg/day danazol. No splenectomy was 
performed, based on the patient’s wishes. The above 
therapeutic regiment maintained platelet count at 40,000– 
50,000 ml 1. At the time of conception, danazol treatment 
was terminated, which resulted in a reduction of platelet 
count to around 20,000 ml 1. At 6 weeks of gestation, the 
platelet count was only 1000–2000  ml 1 while she was 
continuously being treated with 10 mg/day prednisone. An 
increase in the dose of prednisone to 25 mg/day failed to 
increase the platelet count. At 7 weeks of gestation, to 
maintain the platelet count above 20,000 ml 1, she received 
one course of high-dose IVIG at 0.4 g/kg/day for five 
consecutive days, together with 25 mg/day of prednisone. 
After a temporary rise in platelet count (35,000 ml 1), the 
count returned to about 700– 3000 ml 1. Two other courses 
of high-dose IVIG transiently increased platelet count to 
10,000 ml 1, but the effect was transient, lasting for only 1 
week. At 28 weeks of gestation, many petechiae and minor 
purpura were identified on the limbs, which did not 
disappear until childbirth. At 31 weeks of gestation, an 
intractable genital bleeding occurred. Oligohydramnios was 
detected on ultrasound examination during the same week. 
After written informed consent had been obtained, to 
prevent the genital bleeding, a combination therapy with 
high-dose IVIG and danazol (200 mg/day) was immediately 
provided. Three days of such treatment resulted in a rapid 
rise of platelet count to 22,000 ml 1. At 32 weeks and 1 day, 
an emergency Cesarean section was performed following 
the detection of abnormal fetal heart rate. Immediately prior 
to the operation, the patient received 30 U of packed 
platelets. The transfusion of platelets just before laparotomy 
increased the platelet count to 132,000 ml 1 when measured 
intraoperatively. A female infant weighing 1866 g was 
delivered with Apgar scores 9 and 10 at 1 and 5 min, 
respectively. The newborn had no visible physical abnormalities 
including virilization, and the platelet count was 
220,000 ml 1 at delivery. Total blood loss during the 
operation was 1150 ml. All parameters of the coagulation 
system were within the normal limits apart from the platelet 
count. On the seventh postpartum day, the platelet count was 
still about 20,000 ml 1 under treatment with prednisone 
(25 mg/day) and danazol (200 mg/day). Both the mother and 
infant had an uncomplicated postnatal course. The baby 
went home at 4 weeks of age and clinical examination at 18 
months of age showed normal growth and no abnormalities. 
The causal relationship between 3 days of danazol 
therapy and the rise in the patient’s platelet count remains 
unknown. A rise in platelet count induced by danazol often 
takes place after several weeks of administration [3], while 
immunoglobulin increases platelet count within several 
days. In our patient, who had been refractory to IVIG and 
oral glucocorticoid therapy, the effect of the combination 
therapy of high-dose IVIG with danazol was not clear. 
A number of studies have reported that inadvertent use of 
danazol during the first trimester of pregnancy resulted in 
female fetal virilization, including clitoral hypertrophy, 
fused labia, and urogenital sinus malformation [4]. Danazol, 
a synthetic androgen derived from ethisterone, is used for 
the treatment of endometriosis, certain breast disease, and 
ITP. Female fetal genital tissue is very responsive to 
exogenous androgens between 7 and 12 weeks of gestation, 
and continues to exhibit some response until 20 weeks of 
gestation, which can cause variable virilization. However, 
the impact of androgen on fetal virilization seems to be very 
little after 20 weeks of gestation, since the female phenotype 
is complete by 20 weeks of gestation [5], and that excess 
maternal androgen after that stage is converted to estradiol- 
17b by aromatase in both placenta and fetus [6]. The 
influence of danazol on the brain (gender identity, sexual 
behavior, and levels of aggression) remains to be elucidated. 
In contrast, there is no evidence for this side effect when 
danazol is administered in the third trimester. 
Unfortunately, in the present case, effects of danazol 
combined with high-dose IVIG and corticosteroids in the 
third trimester were not unclear. Even in a pregnant woman 
who is refractory to IVIG and oral glucocorticoid therapy, 
combination treatment of high-dose IVIG with corticosteroids 
may not result in successful management. In that case, 
a short-term danazol combined with high-dose IVIG and 
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